Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03833661 · ClinicalTrials.gov registry record · Phase 2
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT03833661 is a Phase 2 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 159 participants.
The verdict
NCT03833661, a Phase 2 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The study to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy.
Interventions
- DRUG M7824
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03833661
The ClinicalTrials.gov registry entry for NCT03833661 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M7824 is the first listed.
NCT03833661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03833661 about?
NCT03833661 is a clinical study titled "M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)". The study to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy.
What is the current status of trial NCT03833661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2019-03-26. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT03833661?
The interventions under investigation include: M7824 (DRUG).
Who is sponsoring clinical trial NCT03833661?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.